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The government of Kazakhstan, a middle-income 
country in Central Asia, is considering the introduction of ro-
tavirus vaccination into its national immunization program. 
We performed a cost-effectiveness analysis of rotavirus 
vaccination spanning 20 years by using a synthesis of dy-
namic transmission models accounting for herd protection. 
We found that a vaccination program with 90% coverage 
would prevent ≈880 rotavirus deaths and save an average 
of 54,784 life-years for children <5 years of age. Indirect 
protection accounted for 40% and 60% reduction in severe 
and mild rotavirus gastroenteritis, respectively. Cost per life 
year gained was US $18,044 from a societal perspective 
and US $23,892 from a health care perspective. Comparing 
the 2 key parameters of cost-effectiveness, mortality rates 
and vaccine cost at <US $2.78 per dose, vaccination pro-
gram costs would be entirely offset. To further evaluate ef-
ficacy of a vaccine program, benefits of indirect protection 
conferred by vaccination warrant further study.
Rotavirus is the leading cause of severe acute gastro-enteritis in children worldwide (1). Rotavirus vac-
cines Rotarix (GlaxoSmithKline Biologicals, Rixensart, 
Belgium) and Rotateq (Merck & Co., Whitehouse Station, 
NJ, USA) are in use in the national immunization programs 
in Australia, the United States, Latin America, and a few 
European countries. In these high- and middle-income 
countries, rotavirus effects have decreased markedly after 
introduction of the vaccine (2–4). Universal rotavirus vac-
cination has not been widely implemented in Asia, and the 
health effects of rotavirus differ considerably across the 
continent, with the highest mortality rates concentrated 
in developing areas. In Central Asia, there are also large 
variations in the reported rotavirus effects by country (5), 
emphasizing the need for local data to guide the decision on 
the introduction of the vaccine.
Kazakhstan is the most prosperous country in Cen-
tral Asia. It has a population of 16 million (6) and a land 
mass equal to approximately half of the continental United 
States. Kazakhstan has large reservoirs of oil and natural 
gas and is classified as an upper-middle income economy; 
its gross national income was US $8,220 per capita in 2011 
(7), making the country ineligible for international funds to 
introduce new vaccines. Vaccines included in the national 
childhood immunization program are fully funded by the 
government. The health effects of rotavirus in Kazakhstan 
were estimated at 68 deaths, 4,007 hospitalizations, and 
32,500 outpatient visits during 2009 (5); another study es-
timated the total annual cost of rotavirus disease to be US 
$37.5 million (8). No current cost-effectiveness analyses of 
rotavirus vaccines were available for Kazakhstan.
Recently, 2 economic evaluations of the rotavirus vac-
cination were conducted in low-income countries in Central 
Asia (9,10), but because of differences in rotavirus epide-
miology, health care costs, and economy, the results are not 
generalizable to Kazakhstan. These studies were performed 
on the basis of static models, which implicitly assume that 
the probability for disease exposure is constant in time. In 
contrast, immunization will not only reduce the probability 
of a vaccinated child to become ill but will also lower the 
exposure of the virus to others (i.e., herd protection). 
Models that account for changes in transmission over 
time are referred to as dynamic models. Cost-effectiveness 
studies of rotavirus vaccination performed on the basis of 
dynamic transmission modeling were recently used in the 
United States (11), England, and Wales (12). To the best 
of our knowledge, this approach has not been applied in 
middle-income countries or in settings with a transitional 
economy. These countries face particular challenges be-
cause they are not eligible for international financing 
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of vaccines, and their resources for new health interven-
tions are limited. Rotavirus vaccine effectiveness has been 
shown to correlate with income level within a country (13). 
It is possible that rotavirus vaccines may perform worse 
in middle-income settings than in upper-income countries. 
Hence, scientifically sound estimates of the effect of rota-
virus vaccination are in demand.
We present a cost-effectiveness study of rotavirus vac-
cination in a middle-income country using dynamic mod-
eling. We incorporated direct effects such as death rates 
and indirect effects such as herd protection of a nationwide 
vaccination program. Our purpose for the study is twofold: 
to inform the impending decision on the introduction of ro-
tavirus vaccination into the national immunization program 
in Kazakhstan, and to compare the cost-effectiveness of a 
rotavirus vaccination program in a middle-income country 
with that reported for high-income settings.
Materials and Methods
We adapted our previously published dynamic model 
for rotavirus (14,15) to Kazakhstan. The model is presented 
in the online Technical Appendix (wwwnc.cdc.gov/EID/
article/20/1/13-0019-Techapp1.pdf).
Vaccination Parameters
We modeled the effect of introducing the 2-dose rota-
virus vaccine Rotarix in the childhood immunization pro-
gram in Kazakhstan. We implemented vaccination in the 
model assuming that the vaccine was effective from the first 
dose at 2 months, similar to other modeling studies (15). 
We chose a 2-dose rotavirus vaccine versus a 3-dose prod-
uct because it may be more feasible in practice to achieve 
high coverage for a vaccine requiring fewer doses. Rotarix 
demonstrated 96% efficacy against rotavirus gastroenteritis 
(RVGE) hospitalizations in clinical trials and 90% field ef-
fectiveness against hospital admissions in high-income Eu-
ropean countries (26). A lower field effectiveness range of 
76%–79% was reported from the middle-income countries 
in Latin America (26–28). Because of lack of clinical tri-
als of rotavirus vaccines in countries like Kazakhstan that 
are in transitional economies, it is difficult to predict the 
vaccine performance in these settings. On the basis of the 
aforementioned findings and our own assumptions, we ap-
plied a vaccine efficacy of 80% (range 72%–86%) against 
severe RVGE and 58% (range 51%–64%) against mild 
RVGE. The vaccine efficacies were varied by varying the 
proportions of RVGE infection, and severe RVGE infec-
tion in vaccinated children (online Technical Appendix). 
We did not adjust the vaccine efficacy for specific rotavirus 
genotypes because the strains circulating in Kazakhstan are 
globally common (29). Pre- and post-licensure data from 
developing settings indicate that vaccine protection may 
wane in the second year of life (30,31). We conservatively 
assumed vaccine protection to be 1 year, commencing after 
administration of the last dose at 4 months of age; that is, 
children were assumed to be fully protected on average un-
til 16 months of age. However, studies from industrialized 
settings demonstrated high vaccine efficacy through 3 years 
of life (32,33). Therefore, we increased duration of vaccine 
protection to 2 years in a separate scenario analysis.
The vaccination program in our model was hypotheti-
cally initiated on January 1, 2012, with a linear buildup of 
vaccine coverage during the first 6 months. After this pe-
riod, the vaccination coverage was assumed to be constant 
at a fixed level. In Kazakhstan, rotavirus vaccine would be 
administered concomitantly with the diphtheria–tetanus 
toxoid–pertussis (DTP) vaccine. The reported coverage for 
3 doses of DTP in Kazakhstan is 99% (7), although a recent 
study suggests that only 76% of children 12–60 months of 
age receive all 3 doses of the DTP vaccine without delay 
(34). Considering age restrictions for the administration of 
rotavirus vaccines, coverage for the rotavirus vaccine may 
be lower than for other traditional vaccines administered 
under the World Health Assembly Expanded Programme 
on Immunization (35) because vaccination may not always 
be on time. We therefore applied 90% coverage in the base 
case, but varied coverage between 80% and 100% to ex-
plore the effect of this parameter on the cost-effectiveness 
of vaccination. Similarly to other studies, we did not con-
sider an increased risk for intussusception or any other ad-
verse events after rotavirus vaccination (2).
Disease Outcomes
We calculated the numbers of rotavirus-associated 
deaths, hospitalizations and outpatient visits in children <5 
years from the modeled incidence of severe RVGE (Is). We 
assumed that all children with severe RVGE require outpa-
tient care or hospital care, and on the basis of local data, we 
modeled that 80% of children who were hospitalized with 
acute diarrhea sought medical care before admission (8). 
We calculated the numbers of rotavirus homecare episodes 
(without health care encounters) from the modeled inci-
dence of mild RVGE (Im), whereas the number of rotavi-
rus-associated deaths and hospitalizations was calibrated to 
the 2009 estimates of 68 (95% CI 63–74) deaths and 4,007 
(95% CI 3,740–4,274) hospitalizations based on a recent 
study from Kazakhstan (8) (online Technical Appendix).
Model Uncertainty and Scenario Analyses
We considered uncertainty related to natural history 
parameters (Table 1), model calibration, and vaccine effi-
cacy and uptake. The role of adults in rotavirus transmis-
sion is a key uncertain factor (15). Because no sentinel 
data in this age group were available, we varied the infec-
tiousness of later rotavirus infections relative to that of the 
primary infection between 1/5 and 1/10 (14,15). We also 
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varied the mean duration of complete immunity after ro-
tavirus infection from 6 to 12 months. All models were 
scored according to how well they fit with the sentinel data, 
adopting a likelihood-based approach by using the Akaike 
information criterion. In total, 5 candidate models (online 
Technical Appendix Table 1) had support and were simulat-
ed, both with and without vaccination. For each model, we 
calculated the yearly numbers of avoided health outcomes 
resulting from incidence difference with and without vac-
cination implemented (online Technical Appendix Table 2).
In the economic analysis, we took a weighted aver-
age of the incidence differences using Akaike weights 
(online Technical Appendix). We modeled several differ-
ent scenarios to account for uncertainty in the calibration 
process, in vaccine efficacy and vaccine uptake (Table 
2). In each scenario, we calculated a weighted model as 
described above. We analyzed a base case (most likely), 
best-case, and worst-case scenario to account for uncer-
tainty instead of adopting a probabilistic approach because 
data on vaccine efficacy and rotavirus-associated health 
outcomes in Kazakhstan are lacking or sparse. In the base 
case, we used mean estimates for both vaccine efficacy 
and calibration values. The best-case scenario was based 
on the highest vaccine efficacy (86% against severe RVGE 
and 64% against mild RVGE), in combination with the up-
per bounds of estimated health outcomes (more events to 
prevent). The worst-case scenario incorporated the low-
est vaccine efficacy (72% against severe RVGE and 51% 
against mild RVGE) and lower estimates of health out-
comes (fewer events to prevent). Vaccine coverage was 
set to 90% in the base case. Scenarios A and B were con-
structed as described above, by using coverage of 80% and 
100%, respectively (online Technical Appendix Tables 3, 
4). Finally, in Scenario C we extended the vaccine protec-
tion period to 2 years in line with data from industrialized 
settings demonstrating high vaccine efficacy through 3 
years of life (32,33). To estimate indirect or herd protec-
tion, we compared predictions of the dynamic model with 
those of a static cohort model, as was previously suggested 
(8) (online Technical Appendix).
Economic Parameters and Cost-effectiveness Analysis
Direct and indirect costs associated with rotavirus 
disease were recently estimated in a cost-of-illness study 
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Table 1. Natural history and vaccine-related parameters used in dynamic modeling of cost-effectiveness of rotavirus vaccination, 
Kazakhstan 
Parameter Base value [range] Reference/source 
Demographic   
 Population during 1980 15,926 million (16) 
 Birth cohort* [217,580–367,750] (16,17) 
 Mortality rate in <1 y* 20–54 per 1,000 births (16,17) 
 Mortality rate in 1–4 y* 3.9–6.3 per 1,000 births (16,17) 
 Net yearly migration rate* 18.6–0.1 per 1,000 (16,17) 
 Deaths per year* [128,570–180,000] (16,17) 
Natural history   
 Duration of maternal protection 70 d (18) 
 Duration of latency period 0.5 d (19) 
 Infectious period (days) 8 (first); 6 (second); 4 (later) (20–22) 
 Relative susceptibility 1 (first); 0.62 (second); 0.40 (later) (23) 
 Relative infectiousness 1 (first); 0.5 (second); [0.1–0.2] (later) Author assumption 
 Proportion of infections with RVGE 0.47(first); 0.25 (second); 0.24 (later) (23) 
     Severe RVGE 0.13 (first); 0.04 (second); 0 (later) (23) 
 Duration of complete immunity [6–12 mo] (24) 
Vaccination   
 Sero-conversion rate 0.96 (25) 
 Relative infectiousness† 
 Relative susceptibility† 
0.5 
0.62 
Assumption 
Author assumption 
 Prop. of infections with RVGE 0.30 [0.25–0.35] (25–27) 
     Severe RVGE 0.1175 [0.0885–0.139] (25–27) 
 Coverage 0.9 [0.8–1.0] Author assumption 
 Duration of complete immunity 12–24 mo] Author assumption 
Fitted‡   
 Infectivity parameter, 0 1.889–2.605 Author calculation 
 Seasonal forcing, 1 0.025–0.046 Author calculation 
 Phase angle,  0.011–0.251 Author calculation 
 Mixing (relative susceptibility)§ 
 0–7m, 8–23 m, 24–35 m 
1.077–2.765 Author calculation 
*Demographic parameters vary over the time period 1980-2031; only minimum and maximum values are listed in the table. All simulations are performed 
using the same set of demographic parameters. 
†Vaccine efficacy calculated for children with no previous natural infection.  
‡Details on the fitted parameters of the five candidate models; see corresponding model fits in online Technical Appendix Table 
wwwnc.cdc.gov/eid/article/20/1/13-0019-Techapp1.pdf; seasonal forcing: 0(1 + 1)sin(2t / 365 + 0).  
§Relative susceptibility in children <3 years (online Technical Appendix, section 1). 
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of RVGE in Kazakhstan (8). These costs included direct 
health care and non–health care costs and indirect costs as-
sociated with productivity losses due to the work absen-
teeism of caregivers and rotavirus-related deaths. For this 
analysis, cost estimates in 2009 US dollars were inflated to 
2012 values by using the consumer price index (Table 3). 
In the absence of a market price for the rotavirus vaccine in 
Kazakhstan, we used the 2010 price of pneumococcal vac-
cine (US $43.00 per dose) purchased by the government. 
Because the vaccine price is a key determinant of cost-
effectiveness, we performed various sensitivity analyses 
with the price ranging from US $1.00 (assuming program 
price for traditional Expanded Programme on Immuniza-
tion vaccines) to US $60.00 per dose (considering a price 
of pneumococcal vaccine that was the most recent vaccine 
introduced in the program in Kazakhstan). The program 
costs included the costs of vaccine doses needed to vac-
cinate the yearly birth cohorts with 2 doses, a 10% vaccine 
wastage, and an additional US $267,300 to cover the costs 
of upgrading the cold chain for rotavirus vaccine in the first 
year of introduction. A 10% loss from vaccine waste was 
based on published estimates (36,37). The yearly costs of 
maintaining the cold chain and the costs of training health 
personnel were estimated in consultation with the Kazakh 
Ministry of Health. We assumed that rotavirus vaccination 
does not incur additional costs to parents because it will be 
administered concomitantly with other vaccines included 
in the national immunization program.
We assessed the aggregated long-term effect of rotavi-
rus vaccination over a 20-year horizon. All costs and health 
outcomes were discounted at a rate of 3.0% per year. We 
conducted cost-effectiveness analyses from the health care 
system’s perspective (including only direct medical costs) 
and the societal perspective (including indirect costs) using 
life-years gained as a measure of benefit. We estimated a 
break-even price for the rotavirus vaccine, in which the to-
tal health care costs of the vaccination program were equal 
to the expected cost savings for the health care system. 
All results are expressed as mean values with a range to 
represent realistic vaccination outcomes given the uncer-
tainty in the epidemiologic model. Lacking actual data on 
uncertainty in the parameter values, we could not express 
uncertainty in terms of statistical distributions, so we chose 
to use 1-way sensitivity analyses.
Results
Base Case
Our model projects that the introduction in Kazakhstan 
of routine rotavirus immunization with 90% coverage and 
a mean duration of vaccine-induced protection of 1 year 
would reduce the incidence of severe and mild RVGE in 
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Table 2. Description of scenarios for the economic evaluation of rotavirus vaccination, Kazakhstan 
Scenario 
Vaccine parameters 
 
Children <5 y of age, calibration to 2009 sentinel data 
Mean duration 
of protection, 
mo Coverage 
Efficacy 
against severe 
RVGE 
Efficacy 
against mild 
RVGE Deaths  
Hospital 
admissions  
Outpatient 
clinic 
visits* 
Homecare 
episodes*  
Base case 12 0.9 0.80 0.58  68 4,007 Is-0.2Ih Im 
Base case, low 12 0.9 0.74 0.51  63 3,740 0.6 0.5Im 
Base case, high 12 0.9 0.86 0.64  74 4,274 1.4 1.5Im 
Scenario A 12 0.89 0.80 0.58  68 4,007 Is-0.2Ih Im 
Scenario A, low 12 0.89 0.74 0.51  63 3,740 0.6 0.5Im 
Scenario A, high 12 0.89 0.86 0.64  74 4,274 1.4( 1.5Im 
Scenario B 12 1.0 0.80 0.58  68 4,007 Is-0.2Ih Im 
Scenario B, low 12 1.0 0.74 0.51  63 3,740 0.6 0.5Im 
Scenario B, high 12 1.0 0.86 0.64  74 4,274 1.4 1.5Im 
Scenario C 24 0.9 0.80 0.58  68 4,007 Is-0.2Ih Im 
Scenario C, low 24 0.9 0.74 0.51  63 3,740 0.6 0.5Im 
Scenario C, high 24 0.9 0.86 0.64  74 4,274 1.4 1.5Im 
*RVGE, rotavirus gastroenteritis; Is, modeled incidence of severe RVGE; Ih, modeled incidence of hospital admissions; Im, modeled incidence of mild 
RVGE. 
†The numbers of outpatient clinic and homecare visits were not calibrated. 
 
 
Table 3. Estimates of projected direct and indirect costs associated with rotavirus disease and rotavirus vaccination, Kazakhstan* 
Item (per case) 
Cost estimates in 2012 US dollars 
Direct Indirect Total Reference/source 
Rotavirus death 543.33 67,254.13 67,799.46 (8) 
Severe case (inpatient care) 364.36 181.47 545.83 (8) 
Moderate case (outpatient care) 32.43 65.57 98.00 (8) 
Mild case (homecare) 3.49 21.86 25.35 (8) 
Cost of vaccine per dose, base case 43.00 0 43.00 Authors’ assumption 
Cold chain upgrade (total first year) 237,300 0 237,300 KMoH 
Training costs (first year) 120,096 0 120,096 KMoH 
Annual cost of cold chain and training 22,037.74 0 22,037.74 KMoH 
*KMoH, Kazakh Ministry of Health. 
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children <5 years of age within the first year (Figure 1, 
panels A, B). After ≈4 years of administration of the vac-
cine program, the dynamics of rotavirus would stabilize, 
and infection would occur with yearly oscillations. Before 
the start of the vaccination, the peak incidence of RVGE 
would be among children <12 months of age. The high-
est incidence of severe and mild disease postvaccination is 
found during the second and third years of life, respectively 
(Figure 1, panels C, D). The age shift is predicted to occur 
within 3 years of vaccination. The yearly peak is predicted 
to be delayed by 14–20 weeks compared with the epidemic 
peak timing without vaccination (online Technical Appen-
dix Figure 4). 
During 20 years of vaccination, the predicted inci-
dence of severe RVGE would be reduced by 74% (base 
case range 64%–80%) of prevaccine levels. The inci-
dence of mild RVGE would be reduced by 56% (range 
45%–64%) compared with incidence among unvaccinated 
children (Figure 1, panels E, F). Our model predicts sub-
stantial indirect or herd protection conferred by rotavirus 
vaccination. The indirect effects account for ≈40% (range 
25–33% in relative terms) of the reduction in the projected 
incidence of severe RVGE, whereas 60% (range 0.28–0.38 
in relative terms) of the incidence drop in mild RVGE 
would be caused by a reduced circulation of rotavirus. Our 
model projects that over 20 years, a vaccination program 
with 90% coverage would prevent 881 (range 776–1,004) 
deaths, 51,891 (range 46,094–57,971) hospital admissions, 
370,268 (range 211,825–541,919) outpatient clinic visits, 
and 1.345 (range 0.641–2.112) million homecare episodes. 
These values correspond to ≈74% (range 70%–77%) avert-
ed deaths, hospitalizations, and outpatient clinic visits and 
55% (range 53%–58%) averted homecare episodes com-
pared with the values predicted without vaccination. In that 
time period, 54,784 (range 48,304–62,442) undiscounted 
life-years are saved (Table 4).
In the base case, the net undiscounted program costs 
would be US $530.7 million; the net costs when account-
ing for cost savings would be US $372.8 (range $325.0–
$416.4) million (Table 4). These results would imply a 
cost of US $23,892 per life-year saved (i.e., incremental 
cost-effectiveness ratio of US $23,892) in a health care 
perspective (range $20,557–$27,573) and US $18,044 in 
a societal perspective ($13,854–$22,779); both estimates 
were discounted at 3%. Figure 2 shows the cost per life-
year gained as a function of the vaccine price per dose 
in a 20-year perspective. At a cost of US $2.78 (range 
$2.01–$3.62), the additional cost of the vaccination pro-
gram would be entirely offset by the cost savings to the 
health care system corresponding to the medical break-
even price.
Scenario Analyses
Varying the vaccination coverage between 80% and 
100% (scenarios A and B) did not substantially influ-
ence the cost-effectiveness ratio (Table 4). For example, 
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Figure 1. Projected epidemiologic effect of rotavirus vaccination in children <5 years of age in Kazakhstan. A) Estimated daily incidence of 
severe RVGE (base case scenario) with introduction of rotavirus vaccination in January 2012 in the 5 candidate models. B) Estimated daily 
incidence of mild RVGE (base case) with introduction of the rotavirus vaccination in January 2012 in the 5 candidate models.  C) Yearly 
age-specific incidence of severe RVGE pre-vaccination (white) and 10 years postvaccination (gray). D) Yearly age-specific incidence of 
mild RVGE pre-vaccination (white) and 10 years postvaccination (gray). E) Relative incidence of severe RVGE with vaccination compared 
with the expected incidence without vaccination; the blue curve shows the mean relative incidence with lower and upper bounds predicted 
by the synthesis of dynamic models, including both direct and indirect effects, while the red curve shows the relative incidence predicted by 
a static cohort model incorporating only the direct effects (online Technical Appendix, wwwnc.cdc.gov/EID/article/20/1/13-0019-Techapp1.
pdf). F) Relative incidence of mild RVGE with vaccination compared with the expected incidence without vaccination; the blue curve shows 
the mean relative incidence with lower and upper bounds in the synthesis of dynamic models; the red curve shows the relative incidence 
predicted by a static cohort model. 
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increasing the coverage to 100% generated only a moder-
ate decrease in the cost per life-year gained (US $23,658 
in a health care perspective and US $17,775  in a societal 
perspective); a marginal change in the cost-effectiveness 
ratio was also observed when vaccine coverage was de-
creased to 80%. We included 6 years without vaccina-
tion to explore any carryover effects after vaccination 
is discontinued. The model predicts that such effects 
are small because infection rates return to prevaccine lev-
els quickly.
Lastly, in scenario C we simulated a 90% vaccine 
coverage assuming 2-year mean vaccine protection (Table 
5; online Technical Appendix Table 5; online Technical 
Appendix Figure 3). These results suggest a cost of US 
$22,579 per life-year saved in a health care perspective and 
US $16,775 in a societal perspective; the medical break-
even price was estimated at a cost of US $ 2.95 per dose. 
Compared with the base case (Table 4), assuming 2 years 
of vaccination protection reduced the cost per life-year 
saved by 5.5% in a health care perspective and 7.4% in a 
societal perspective.
Discussion
Our study evaluated the cost-effectiveness of rotavirus 
vaccination in a middle-income country by use of a dynam-
ic model. The results indicate that universal rotavirus vac-
cination in Kazakhstan could prevent 800–1,000 deaths, 
46,000–58,000 hospitalizations, 210,000–540,000 outpa-
tient clinic visits, and 0.6–2.1 million homecare episodes 
during the next 2 decades. Our study suggests that the cost-
effectiveness of rotavirus vaccination is determined by 2 
key factors: the ability of the vaccines to prevent severe 
RVGE in children and the market price of the vaccine. 
Vaccination also reduces productivity losses because 
of lower mortality rates and less work absenteeism among 
parents. However, the small difference between the 
cost-effectiveness ratios with and without indirect costs 
is explained by the dominant role of the vaccine costs. 
In the economic analysis, we calculated the break-even 
price, representing the price at which the costs of vac-
cination would be offset by the health care cost savings 
from avoided cases. With vaccine prices below the break-
even price, the vaccination program would become one of 
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Table 4. Estimated projected costs in million US dollars and avoided health outcomes of rotavirus vaccination program in Kazakhstan, 
2012–2031 
Outcome 
No 
vaccination 
Base case, 90% vaccine 
coverage, 1-y vaccination 
protection 
 
Scenario A, 80% vaccine 
coverage, 1-y vaccination 
protection 
 
Scenario B, 100% vaccine 
coverage, 1-y vaccination 
protection 
Mean Low High Mean Low High Mean Low High 
 
 Avoided outcomes, undiscounted 
Fatal cases 1,310 880 776 1,004  777 681 890  985 876 1 114 
In-hospital 
care 
77,205 51,891 46,094 57,971  45,802 40,436 51,447  58,086 52,038 64,396 
Out-patient  
visits 
550,896 370,268 211,825 541,919  326,820 185,825 480,935  414,473 239,145 601,983 
Home care 
episodes 
2,675,456 1,344,747 640,836 2,112,400  1,163,780 552,160 1,835,487  1,544,096 740,039 2,412,843 
Life years 
gained 
 54,784 48,304 62,442  48,356 42,375 55,416  61,325 54,534 69,363 
Vaccination  530.7 530.7 530.7  471.9 471.9 471.9  589.6 589.6 589.6 
In-hospital 
care 
25.7 18.9 16.8 21.2  16.7 14.7 18.7  21.2 18.9 23.5 
Out-
hospital 
care 
16.3 12.0 6.9 17.6  10.6 6.0 15.6  13.4 7.8 19.5 
Homecare 8.5 4.7 2.2 7.4  4.1 1.9 6.4  5.4 2.6 8.4 
Indirect 
costs 
179.4 122.3 88.4 159.7  107.4 77.4 140.9  137.7 100.3 178.9 
Total net 
costs 
229.9 372.8 416.4 325.0  333.1 371.8 290.2  411.9 460.1 359.3 
 Incremental cost-effectiveness ratios, societal perspective 
Discounted 
3% 
NA 18,044 22,779 13,854  18,280 27,991 13,955  17,775 22,250 13,768 
 Incremental cost-effectiveness ratios, health care perspective 
Discounted 
3% 
NA 23,892 27,573 20,557  24,102 23,210 20,620  23,658 27,061 20,526 
 Threshold prices, 3% discounting 
Medical 
break-even 
price† 
NA $2.78 $2.01 $3.62  $2.78 $1.96 $3.60  $2.83 $2.05 $3.65 
*Negative values indicate prevented or avoided costs. NA, not applicable. 
†The price per vaccine dose at which the vaccinations costs are offset by cost saving generated from lower morbidity and mortality rates. 
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cost saving. We believe that estimating cost per life-year 
gained and the break-even price of vaccine is informative 
for decision makers negotiating the price with manufac-
turers in the absence of an established market price for the 
product. Whether the cost per life-year represents value 
for money and is considered cost-effective is a political 
question for Kazakhstan authorities to decide. WHO has 
suggested that governments should be willing to pay 3 
times gross domestic product per capita per year for a 
good life-year. For Kazakhstan, this would amount to 
US $24,660.
A strength of this study is that the results are a syn-
thesis of 5 models and use a likelihood-based approach, 
in which the models are weighted according to their 
ability to fit the sentinel data. This approach is common 
in weather and finance models but not in infectious dis-
ease modeling.
Our model demonstrates the role of indirect protec-
tion conferred by rotavirus vaccination. In our base case 
scenario, herd protection accounted for a 40% reduction 
in the incidence of severe RVGE and a 60% decrease in 
the incidence of mild RVGE. The contribution of indi-
rect effects to the overall effect of vaccine is an obser-
vation also reported by other dynamic modeling studies 
and supported by empirical data from countries already 
using rotavirus vaccine in routine immunization programs 
(2,3). The incidence reduction in our model is larger than 
that found by Atkins et al. in a study from England and 
Wales, where 25% and 40% of the incidence reduction 
in severe and mild RVGE, respectively, were accounted 
for by herd protection, assuming a 1-year mean vaccine 
protection (38). This difference may be attributed to dif-
ferences in assumptions on vaccine-related parameters, 
the magnitude of the disease burden, population dynam-
ics and other model characteristics. This model has previ-
ously been fitted to data from England and Wales with 
a basic reproductive number of the primary infection of 
R0 = 17.6 (15), which is smaller than the value estimated 
for Kazakhstan of R0 = 19.2 – 2104, thereby suggesting 
higher transmission pressure in the latter setting. 
Data from Finland suggest that vaccine protection may 
last for >1 year (39). We have also tested the model as-
suming 2 years of vaccine-derived protection. In this case, 
we found less indirect protection against severe RVGE, 
roughly representing 20% of the reduction (Table 5; online 
Technical Appendix Figure 3). The direct effect from vac-
cination increases because it is calculated from the expect-
ed infections in vaccinated children 2–28 months of age, 
had they not been vaccinated, versus children 2–16 months 
of age in the base case. We obtained a modest effect from 
extending the vaccine protection period by 1 year, which 
may be related to our use of a mean value for the vaccine 
duration instead of a fixed duration of vaccine protection, 
implying that some children will experience a shorter dura-
tion of protection.
We decided to provide a conservative estimate of 
the cost-effectiveness of rotavirus vaccination. First, we 
assumed that direct vaccine-derived protection lasts for 
1 year because data on a longer duration of vaccine pro-
tection from industrialized countries may not be directly 
generalizable to Kazakhstan. Second, we assumed that the 
risk for severe RVGE is age-independent. Vaccination in-
creases the average age of infection, and it is plausible that 
this risk for severe RVGE is lower for older versus younger 
children. Third, we applied a lower estimate of vaccine ef-
ficacy in our model because Kazakhstan is a developing 
nation. However, if rotavirus vaccines demonstrate a better 
efficacy in this country, it may substantially influence the 
cost-effectiveness of vaccination.
Several limitations in our study warrant care in inter-
pretation of the results. First, our model was fitted to the 
2-year sentinel hospital data on rotavirus surveillance on 
the basis of information from 2 hospitals; hence, changes 
in annual RVGE incidence and seasonality may have not 
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per life-year gained over a 20-
year time period (2012–2031) 
after introduction of rotavirus 
vaccination in Kazakhstan, 
according to purchasing price of 
1 vaccine dose.
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been fully captured. Likewise, local data on outpatient 
visits are sparse. We have attempted to compensate for 
this by using wide upper and lower confidence bounds on 
these estimates. Second, the parameters used to charac-
terize natural rotavirus infections were based on those in 
a study conducted in Mexico and may not properly rep-
resent the epidemiology of rotavirus infections in Cen-
tral Asia. Third, we used continuous aging in the model, 
which may have introduced a bias arising from persons 
aging at different rates. Even so, we used a small age band 
of 1 month, and we tested the model performance without 
finding severe bias (14). Fourth, the choice of simulation 
period may imply that carryover effects beyond 20 years 
were disregarded, but the scenario analysis indicates that 
such effects are small and will not influence the ICERs 
because of discounting. Fifth, we tested the uncertainty of 
the vaccine price in the sensitivity analysis, but because 
of lack of data, we were unable to test the uncertainty of 
other cost parameters in the model. Finally, because of 
lack of data, we disregarded improved quality of life in 
the economic analysis.
In conclusion, rotavirus vaccination in Kazakhstan 
will provide considerable direct health benefits in terms of 
reduced illness and deaths. Using the WHO criterion for 
cost-effectiveness, vaccination would be considered cost-
effective under most of the assumptions of our analyses. 
With a low vaccine price, the avoided disease costs from 
vaccination will be greater than the vaccination costs. 
Further study is warranted to measure the benefits of herd 
immunity conferred by vaccination and to add that infor-
mation to the current comparison of the costs of illness to 
those of a national vaccine program.
Dr Freiesleben de Blasio works at the Norwegian Institute of 
Public Health and the University of Oslo. Her research interests 
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